Cargando…

Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer

BACKGROUND: Immunotherapy has become a key component of systemic therapy in stage IV non-small cell lung cancer (NSCLC). However, there have been conflicting reports of its efficacy in patients with liver metastasis (LM). METHODS: Using National Cancer Database (NCDB), patients who have been diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komiya, Takefumi, Takamori, Shinkichi, Shimokawa, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409553/ https://www.ncbi.nlm.nih.gov/pubmed/37560341 http://dx.doi.org/10.14740/wjon1625

Ejemplares similares

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Clinical impact of number of lymph nodes dissected on postoperative survival in node-negative small cell lung cancer
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC
por: Komiya, Takefumi, et al.
Publicado: (2020)

Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials
por: Takada, Kazuki, et al.
Publicado: (2022)

Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung
por: Komiya, Takefumi, et al.
Publicado: (2021)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Impact of the pretreatment prognostic nutritional index on the survival after first‐line immunotherapy in non‐small‐cell lung cancer patients
por: Oku, Yuka, et al.
Publicado: (2023)

Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?
por: Takenaka, Tomoyoshi, et al.
Publicado: (2023)

Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series
por: Dasari, Srikiran, et al.
Publicado: (2022)

Re: COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)
por: Takada, Kazuki, et al.
Publicado: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Takada, Kazuki, et al.
Publicado: (2021)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
por: Takada, Kazuki, et al.
Publicado: (2022)

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer
por: Shoji, Fumihiro, et al.
Publicado: (2022)

Systematic analysis of design and stratification for phase III trials in first‐line advanced non‐small cell lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2015)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Recent trends in use of adjuvant chemotherapy in elderly stage II–III non-small cell lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2020)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2020)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2022)

Patterns of care for older patients with stage IV non‐small cell lung cancer in the immunotherapy era
por: Kehl, Kenneth L., et al.
Publicado: (2020)

Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer
por: Patel, Krishna H., et al.
Publicado: (2023)

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
por: Deslypere, Griet, et al.
Publicado: (2018)

Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’
por: Takada, K., et al.
Publicado: (2022)

Correspondence Regarding “Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study”
por: Takada, Kazuki, et al.
Publicado: (2023)

Small Bowel Perforation Due to Rare Metastasis From Stage IV Lung Adenocarcinoma
por: Sautto, Francesco, et al.
Publicado: (2022)

The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life
por: Park, Rebekah, et al.
Publicado: (2020)

Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non–Small Cell Lung Cancer Treated With First-Line Therapy
por: Ma, Xinran, et al.
Publicado: (2022)

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
por: Huang, Chengliang, et al.
Publicado: (2020)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer
por: Yang, Szu‐Chun, et al.
Publicado: (2023)

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer
por: Bratova, Monika, et al.
Publicado: (2023)

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
por: Liu, Yang, et al.
Publicado: (2023)

Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy
por: Williams, Christina D., et al.
Publicado: (2023)

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
por: Suzuki, R, et al.
Publicado: (2006)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ka9j76uujl21oj1rgm454m0mhb